Celgene Reports Third Quarter 2017 Operating and Financial Results

Go back to Celgene Reports Third Quarter 2017 Operating and Financial Results

Celgene (CELG) PT Lowered to $125 at Jefferies; Reiterates Buy

October 27, 2017 8:40 AM EDT

Jefferies lowered its price target on Celgene (NASDAQ: CELG) to $125.00 (from $160.00) while maintaining a Buy rating.

While clearly a disappointment and large market reaction, moving forward the question is what could turn this around. Analyst Michael Yee thinks at $95 (close to $80-85 no pipeline value), it's overdone in bigger picture.

... More

Celgene (CELG) Tops Q3 EPS by 4c, Sales Miss; Raises Low End of FY EPS Guidance, Offers 2020 Targets

October 26, 2017 7:34 AM EDT

Celgene (NASDAQ: CELG) reported Q3 EPS of $1.91, $0.04 better than the analyst estimate of $1.87. Revenue for the quarter came in at $3.29 billion versus the consensus estimate of $3.42 billion.

GUIDANCE:

Celgene sees FY2017 EPS of $7.30-$7.35, versus the consensus of... More